

REPOS THERAPEUTICS INC.

Form 8-K

January 21, 2014

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

**PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): January 16, 2014

Repos Therapeutics Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware 001-15281 76-0233274

(State or Other (Commission File (I.R.S. Employer

Jurisdiction of Number) Identification No.)

Edgar Filing: REPROS THERAPEUTICS INC. - Form 8-K

Incorporation)

2408 Timberloch Place, Suite B-7
The Woodlands, TX 77380
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (281) 719-3400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- “Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
- “Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
- “Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b)).
- “Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c)).

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 16, 2014, the Compensation Committee of the Board of Directors of Repros Therapeutics Inc. (the “Company”) approved a grant to Katherine Anderson, the Company’s Chief Financial Officer, of options to purchase 5,000 shares of the Company’s common stock, \$0.001 per share (the “Common Stock”), as compensation for her work in 2013. The options, which were granted under the Company’s 2011 Equity Incentive Plan, have a per share exercise price of \$21.48, the closing price of the Common Stock on the Nasdaq Stock Market on the date of grant, a term of 10 years, and will vest in quarterly installments over the three years following the date of grant.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**REPROS
THERAPEUTICS INC.**

By: /s/ Katherine Anderson
Katherine Anderson
CFO

Dated: January 21, 2014